Page last updated: 2024-08-24

falintolol and Glioma

falintolol has been researched along with Glioma in 1 studies

*Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Conti, P; Dallanoce, C; De Amici, M; De Micheli, C; Klotz, KN1

Other Studies

1 other study(ies) available for falintolol and Glioma

ArticleYear
Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists.
    Bioorganic & medicinal chemistry, 1998, Volume: 6, Issue:4

    Topics: Adenylyl Cyclases; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Binding, Competitive; CHO Cells; Chromatography, Thin Layer; Cricetinae; Glioma; Humans; Isoxazoles; Magnetic Resonance Spectroscopy; Pindolol; Propanolamines; Radioligand Assay; Rats; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Tumor Cells, Cultured

1998